蕈样肉芽肿病伴 CD30 阳性大细胞转化经 Brentuximab vedotin 治疗后成功缓解。
Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
机构信息
Clinic of Dermatovenereology, Clinical Center of Serbia, Belgrade, Serbia.
Department of Dermatovenereology, School of Medicine, University of Belgrade, Belgrade, Serbia.
出版信息
Dermatol Ther. 2020 Jan;33(1):e13152. doi: 10.1111/dth.13152. Epub 2019 Nov 19.
We present a patient with a 33-year history of poikilodermatous mycosis fungoides (MF) who subsequently developed CD30-positive large cell transformation. After 6 years of conventional MF treatment, side effects of therapy and/or concomitant diseases prevented the previously applied treatment modalities. The CD30-directed antibody-cytotoxic drug conjugate (brentuximab vedotin) was introduced and followed by quick and excellent therapeutic response.
我们报告了一例患有斑状蕈样肉芽肿（MF）33 年病史的患者，随后发展为 CD30 阳性的大细胞转化。经过 6 年的常规 MF 治疗，治疗的副作用和/或并存疾病使先前应用的治疗方法无法进行。引入了靶向 CD30 的抗体-细胞毒性药物偶联物（ Brentuximab vedotin），随后迅速产生了极好的治疗反应。
Zotero 插件